Sequential monotherapy with BRAF, MEK, and ERK inhibitors was ineffective to prevent BRAFampl development; concurrent treatment with these inhibitors delayed the occurrence of BRAFampl; intermittent treatment with this combination of drugs prevents BRAFampl, and is able to inhibit tumor proliferation in 100% of cases [33]. The gene discussed is MAP2K7; the disease is neoplasm.